| Identification | Back Directory | [Name]
3-Amino-6-[4-[[4-[4-[1-[17-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]-3,6,9,12,15-pentaoxaheptadec-1-yl]-1H-1,2,3-triazol-4-yl]butyl]-1-piperazinyl]sulfonyl]phenyl]-N-3-pyridinyl-2-pyrazinecarboxamide | [CAS]
2721998-87-2 | [Synonyms]
PT-65
3-Amino-6-[4-[[4-[4-[1-[17-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]-3,6,9,12,15-pentaoxaheptadec-1-yl]-1H-1,2,3-triazol-4-yl]butyl]-1-piperazinyl]sulfonyl]phenyl]-N-3-pyridinyl-2-pyrazinecarboxamide | [Molecular Formula]
C51H63N13O12S | [MOL File]
2721998-87-2.mol | [Molecular Weight]
1082.19 |
| Chemical Properties | Back Directory | [density ]
1.46±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | [form ]
Solid | [pka]
7.17±0.70(Predicted) | [color ]
Light yellow to green yellow |
| Hazard Information | Back Directory | [Uses]
PT-65 is a potent and selective GSK3 PROTAC degrader with the highest degradation capacity of GSK3α (DC50= 28.3 nM) and GSK3β (DC50= 34.2 nM) in SH-SY5Y cells. PT-65 can be used in Alzheimer's disease research[1].(Pink: GSK3 inhibitor (HY-15761); Black: linker; Blue: CRBN Ligand (HY-10984)) | [References]
[1] Qu L, et al. Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease. Eur J Med Chem. 2021 Dec 15;226:113889. DOI:10.1016/j.ejmech.2021.113889 |
|
|